COPLEY COPES WITH CONTAINMENT CRISIS; STOCK RECOVERS TWO POINTS IN APRIL
Executive Summary
Copley Pharmaceutical appears to be turning the corner on Wall Street: the company posted a two-point gain in April to close at 26 after a 40% decline in value during the first three months of 1994 prompted by a Class I recall of albuterol solution. Investors warmed to the stock after Copley released test results showing that the contaminating organism in Copley's recalled albuterol was an environmental bacterium that rarely causes illness ("The Pink Sheet" April 4, T&G-13).